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Summary
Background.  —  National  population-based  management  and  outcome  data  for  patients  of  all
ages hospitalized  for  heart  failure  have  rarely  been  reported.
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Aim.  —  National  population-based  management  and  outcome  of  patients  of  all  ages  hospitalized
for heart  failure  have  rarely  been  reported.  The  present  study  reports  these  results,  based  on
77% of  the  French  population,  for  patients  hospitalized  for  the  ﬁrst  time  for  heart  failure  in
2009.
Methods.  —  The  study  population  comprised  French  national  health  insurance  general  scheme
beneﬁciaries  hospitalized  in  2009  with  a  principal  diagnosis  of  heart  failure,  after  exclusion  of
those hospitalized  for  heart  failure  between  2006  and  2008  or  with  a  chronic  disease  status
for heart  failure.  Data  were  collected  from  the  national  health  insurance  information  system
(SNIIRAM).
Results. —  A  total  of  69,958  patients  (mean  age,  78  years;  48%  men)  were  studied.  The  hos-
pital mortality  rate  was  6.4%,  with  1-month,  1-year  and  2-year  survival  rates  of  89%,  71%  and
60%, respectively.  Heart  failure  and  all-cause  readmission-free  rates  were  55%  and  43%  at  1
year and  27%  and  17%  at  2  years,  respectively.  Compared  with  a  reference  sample  of  600,000
subjects, the  age-  and  sex-standardized  relative  risk  of  death  was  29  (95%  conﬁdence  interval
[CI] 28—29)  at  2  years,  82  (95%  CI  72—94)  in  subjects  aged  <  50  years  and  3  (95%  CI  3—3)  in
subjects aged  ≥  90  years.  For  subjects  aged  <  70  years  who  survived  1  month  after  discharge,
factors associated  with  a  reduction  in  the  2-year  mortality  rate  were:  female  sex;  age  <  55  years;
absence  of  co-morbidities;  and  use  of  angiotensin-converting  enzyme  inhibitors  or  angiotensin
receptor  blockers,  beta-blockers,  lipid-lowering  agents  or  oral  anticoagulants  during  the  month
following discharge.  Poor  prognostic  factors  were  treatment  with  a  loop  diuretic  before  or  after
hospitalization  and  readmission  for  heart  failure  within  1  month  after  discharge.
Conclusions.  —  This  large  population-based  study  conﬁrms  the  severe  prognosis  of  heart  failure
and the  need  to  promote  the  use  of  effective  medications  and  management  designed  to  improve
survival.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  prise  en  charge  et  le  devenir  de  patients  hospitalisés  pour  insufﬁsance  cardiaque
(IC) à  un  niveau  national  et  tous  âges  confondus,  est  rarement  rapporté.
Objectif.  —  C’est  le  cas  de  cette  étude  sur  77  %  de  la  population  franc¸aise  pour  des  patients
avec une  première  hospitalisation  pour  IC  en  2009.
Méthodes.  —  Parmi  les  bénéﬁciaires  du  régime  général  de  l’Assurance  maladie  hospitalisés  en
2009 avec  un  diagnostic  principal  d’IC  ont  été  exclus  ceux  hospitalisés  pour  IC  entre  2006  et
2008 ou  avec  une  affection  de  longue  durée  pour  IC.  Les  données  utilisées  étaient  celles
présentes  dans  le  système  d’information  de  l’Assurance  maladie  (SNIIRAM).
Résultats.  —  Au  total,  69  958  patients  ont  été  inclus  (âge  moyen  78  ans,  48  %  d’hommes).  Leur
taux de  décès  hospitalier  était  de  6,4  %.  Leurs  taux  de  survie  étaient  de  89  %  à  un  mois,  71  %  à  un
an et  de  60  %  à  deux  ans.  Ceux  sans  réhospitalisation  pour  IC  étaient  de  55  %  à  un  an  et  de  43  %  à
deux ans  et  sans  réhospitalisation  toutes  causes  respectivement  de  27  %  et  17  %.  Comparative-
ment à  un  échantillon  permanent  par  tirage  au  sort  de  600  000  assurés,  leur  risque  relatif  de
décès à  2  ans,  standardisé  sur  l’âge  et  le  sexe,  était  de  29  (95  %  CI  28—29)  et  chez  les  moins  de
50 ans  de  82  (95  %  CI  72—94)  et  de  3  (95  %  CI  3—3)  chez  ceux  de  90  ans  et  plus.  Pour  les  moins  de
70 ans  ayant  survécu  un  mois  après  leur  sortie,  les  facteurs  positifs  associés  au  décès  à  deux  ans
étaient le  sexe  féminin,  l’âge  inférieur  à  55  ans,  l’absence  de  comorbidités,  une  consommation
le mois  de  sortie  d’IEC-sartan,  de  bêtabloquant,  d’hypolipémiant,  d’anticoagulant  oral.  Parmi
les facteurs  péjoratifs,  il  était  retrouvé  un  traitement  par  diurétique  de  l’anse  avant  ou  après
hospitalisation  et  une  réhospitalisation  pour  IC  le  mois  de  sortie.
Conclusion.  — Cette  étude  sur  une  large  population  conﬁrme  la  sévérité  du  pronostic  de  l’IC,  la
nécessité  de  favoriser  l’utilisation  de  médicaments  bénéﬁques  et  de  prises  en  charge  limitant
les réhospitalisations.
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BackgroundHeart  failure  is  a  disabling  and  complex  syndrome,  with  a
high  prevalence  (2%  of  the  Western  population,  10%  after
the  age  of  75  years)  that  is  still  increasing,  together  with
the  associated  healthcare  consumption  [1—4].  Nevertheless,
b
t
3
as  droits  réservés.
tandardized  hospitalization  rates  for  heart  failure  are  glob-
lly  tending  to  decline  in  several  countries,  such  as  France,
ut  the  readmission  rate  remains  high  [2,5—8].  In  the  USA,
he  proportion  of  Veterans  readmitted  to  hospital  within
0  days  following  discharge  was  5.6%  for  heart  failure
nd  22%  for  all  causes  (2002—2006)  —  similar  to  the  23%
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eadmission  rate  for  Medicare  beneﬁciaries  (2004—2006)
9,10].  In  France,  21%  of  all  patients  hospitalized  for  heart
ailure  in  2008  were  readmitted  to  hospital  at  least  once  for
eart  failure  during  the  same  calendar  year.  Early  readmis-
ions  for  heart  failure  have  multiple  causes,  and  therapeutic
atient  education  and  management  programmes  are  rec-
mmended  at  the  time  of  discharge  from  hospital  [11,12].
n  improvement  in  survival  has  been  reported,  particularly
fter  a  ﬁrst  hospitalization,  but  the  prognosis  neverthe-
ess  remains  poor  [7,13,14].  Reported  survival  rates  vary
ccording  to  the  period  and  the  mode  of  patient  selec-
ion,  but  also  to  sociodemographic  and  clinical  case  mixes
1,3,4].  Patients  with  heart  failure  have  a  high  mortality
ate  compared  with  the  general  population,  but  this  has
arely  been  compared  by  sex  and  age  group  in  large  popula-
ions  [15].  Clinical  trials  have  demonstrated  in  speciﬁc  age
roups  the  beneﬁt  of  a  number  of  drugs  in  terms  of  survival,
uch  as  angiotensin-converting  enzyme  inhibitors  (ACEIs),
ngiotensin  receptor  blockers  (ARBs)  and  beta-blockers,
ven  if  their  use  is  suboptimal  [12,16,17].
This  observational  study  in  patients  of  all  ages  derived
rom  a  large  comprehensive  population  (77%  of  the  French
opulation)  hospitalized  for  the  ﬁrst  time  for  heart  failure
n  2009  and  followed  for  2  years,  aimed  to  determine  the
eadmission  and  mortality  rates  compared  with  a  reference
opulation  and  to  assess  factors  associated  with  mortality
mong  survivors  after  hospital  discharge.
ethods
nformation system and population
n  France,  the  Système  national  d’information  inter-régimes
e  l’assurance  maladie  (SNIIRAM;  French  national  inter-
cheme  health  insurance  information  system)  comprises
n  individual  and  anonymous  database  concerning  the
eneﬁciaries  of  the  various  schemes  [18].  The  database  com-
rehensively  records  all  outpatient  prescriptions,  services
nd  procedures  performed  and  reimbursed,  together  with
heir  dates.  Historical  data  are  limited  to  a  period  of  3  years
lus  the  current  year.  Medications  are  identiﬁed  accord-
ng  to  Anatomical  Therapeutic  Classiﬁcation  (ATC)  code  and
aboratory  tests  are  identiﬁed  from  the  French  national
aboratory  test  coding  table.  Although  the  database  does
ot  contain  any  clinical  information  concerning  the  results
elated  to  prescriptions  or  examinations,  it  nevertheless
ndicates  the  presence  of  any  ‘‘affections  de  longue  durée’’
ALD;  chronic  diseases),  eligible  for  100%  reimbursement
f  healthcare  expenditure,  such  as  cardiovascular  diseases,
fter  application  by  the  attending  physician  and  approval
y  the  national  health  insurance  consultant  physician.  An
nonymous  unique  identiﬁcation  number  for  each  subject
inks  this  information  to  data  collected  by  the  national
ospital  discharge  database  (PMSI:  Programme  de  médical-
sation  des  systèmes  d’information) in  public  and  private
ealthcare  institutions.  During  the  patient’s  stay,  principal
iagnoses  (PDs),  associated  diagnoses  (ADs)  and  any  ALD
hronic  diseases  are  coded  according  to  the  tenth  Inter-
ational  Classiﬁcation  of  Diseases  (ICD-10).  In  parallel,  this
atabase  also  provides  a  permanent  open  randomized  sam-
le  (Échantillon  Permanent  des  Bénéﬁciaires) representing
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/97th  of  all  national  health  insurance  schemes  beneﬁciar-
es  (600,000  subjects)  and  one  of  the  main  advantages  of
his  sample  is  the  exhaustiveness  of  survival  data.
The  study  population  was  limited  to  beneﬁciaries  of  the
ational  health  insurance  general  scheme  (77%  of  the  64
illion  inhabitants  in  France  in  2009),  excluding  those  cov-
red  by  local  mutualist  sections  (students,  civil  servants,
tc.),  the  Mutualité  Sociale  Agricole,  the  Régime  Social
es  Indépendants  and  other  speciﬁc  health  insurance.  The
easons  for  limiting  the  study  to  this  population  were  the
vailability  of  vital  status  and  date  of  death  from  the
ational  Institute  for  Statistics  and  Economic  Studies  (INSEE)
or  the  general  scheme  in  the  SNIIRAM  and  the  lack  of  com-
leteness  for  some  SNIIRAM  characteristics  in  some  other
chemes.  To  optimally  target  ﬁrst  hospitalizations  for  heart
ailure,  patients  hospitalized  with  a  PD  of  heart  failure  (ICD-
0  code  I50)  in  2009,  but  not  between  2006  and  2008,  and
lso  not  presenting  an  ALD  status  for  heart  failure  were
elected  for  this  study.  Patients  hospitalized  in  2008  with
n  AD  of  heart  failure  were  also  excluded.  Hospitalizations
ith  the  following  PDs  were  not  included:  I11.0  hypertensive
eart  disease;  I13.0  hypertensive  heart  and  renal  disease
ith  (congestive)  heart  failure;  I13.2  hypertensive  heart  and
enal  disease  with  (congestive)  heart  failure  and  renal  fail-
re;  I13.9  hypertensive  heart  and  renal  disease,  unspeciﬁed;
76.1  chronic  passive  congestion  of  liver;  and  J81  pulmonary
edema.
eﬁnitions and statistical analysis
atient  characteristics  and  management
he  search  for  co-morbidities  before  the  ﬁrst  hospitaliza-
ion  for  heart  failure  took  into  account  the  presence  of
peciﬁc  chronic  diseases  identiﬁed  by  ICD-10  codes.  Drug
reatments  were  identiﬁed  by  the  presence  of  at  least
hree  reimbursements  during  the  6  months  preceding  the
ndex  hospitalization  and  by  a single  reimbursement  dur-
ng  the  30  days  following  discharge  among  patients  still
live.  The  absence  of  all-class  medications  reimbursements
uring  these  two  periods  was  also  studied  in  order  to  iden-
ify,  especially  among  the  oldest  patients,  those  living  in
n  institution  that  manages  medicinal  products  directly  and
or  whom  no  information  on  drug  consumption  is  therefore
ecorded  in  the  SNIIRAM  database.  Reimbursements  for  hos-
ital  outpatient  clinic  and  ofﬁce  visits  were  used  to  identify
ardiology  consultations.  As  echocardiography  is  not  system-
tically  coded  during  a  cardiology  visit,  because  the  levels
f  reimbursement  may  be  similar  for  a visit  with  or  without
chocardiography,  a  variable  was  constructed  by  combin-
ng  the  existence  of  at  least  one  visit  to  the  cardiologist  or
chocardiography.
eadmission,  survival  and  risk  factors  associated
ith mortality
urvival  rates  were  calculated  for  the  overall  patient  popu-
ation  (including  hospital  deaths).  The  2-year  mortality  was
ompared  with  that  of  the  Échantillon  Permanent  des  Béné-
ciaires  sample,  with  standardization  according  to  sex  and
ge,  and  calculation  of  relative  risk  (RR)  and  95%  conﬁ-
ence  intervals  (CIs).  Readmissions  were  taken  into  account
nly  when  they  occurred  at  least  7  days  after  discharge,
ilure  161
Table  1  Outcome  of  patients  after  a  ﬁrst  hospitaliza-
tion  for  heart  failure  in  2009,  according  to  age.
Time  since  discharge  (months)
1  6  12  24
Survivala (%)
All  ages 89.2 78.3 70.8 59.7
< 55  years 96.3 91.9 88.8 84.6
55—69  years  94.7  88.6  84.0  77.1
70—79  years  92.6  83.7  77.4  68.0
80—89  years  87.2  74.6  65.7  52.3
≥  90  years  78.5  60.6  49.7  34.3
Survival  without  readmission  for  heart  failure
(%)
Total  84.6  64.7  54.8  42.6
<  55  years  91.5  77.5  70.0  64.5
55—69  years  89.4  73.9  64.9  56.4
70—79  years  87.8  68.9  59.5  48.5
80—89  years  82.8  61.6  51.0  36.9
≥  90  years  75.0  49.6  38.8  24.4
Survival  without  readmission  for  all  causes  (%)
Total 73.1  38.7  26.8  16.7
<  55  years 75.4 40.3  32.2  26.2
55—69  years 74.1  39.5  28.5  19.9
70—79  years 74.2 39.2  27.3  17.0
80—89  years 73.0 39.1 26.4  15.2
≥  90  years 68.6 34.3 22.5 11.6
At  least  one  readmission  for  heart  failure
without  death  (%)
Total  4.6  13.6  15.8  16.5
<  55  years  4.8  14.4  16.4  18.5
55—69  years  5.3  14.7  17.5  19.4
70—79  years  4.9  14.8  17.5  19.5
80—89  years  4.4  13.0  15.2  15.2
≥  90  years  3.5  11.1  12.0  12.4
a Including hospital deaths.
Figure 1. Age- and gender-adjusted 2-year mortality rates ofOutcome  of  patients  after  a  ﬁrst  hospitalization  for  heart  fa
in  order  to  avoid  considering  early  transfers.  Readmissions
were  studied  according  to  the  presence  of  a  PD  or  AD  of
heart  failure  or  an  all-cause  PD.  Readmission-free  survival
rates  (all-cause  or  heart  failure)  were  also  calculated.  Read-
mission  rates  for  heart  failure  were  also  calculated  with
censoring  of  deaths,  i.e.  based  on  all  patients  still  alive  at
the  end  of  the  period  considered.  The  presence  of  at  least
one  readmission  —  or  the  ﬁrst  readmission  —  was  reported
according  to  the  principal  diagnoses  coded  and  was  grouped
according  to  the  main  chapters  of  ICD-10  for  patients  still
alive  at  2  years.
To evaluate  the  available  factors  possibly  associated  with
survival,  the  ﬁrst  step  in  the  study  consisted  of  descriptive
analysis  of  the  patients  surviving  30  days  after  discharge
and  presenting  at  least  one  all-class  medicinal  product
reimbursement  6  months  before  and  1  month  after  hospi-
talization.  Univariate  and  then  multivariable  Cox  models
were  used  to  identify  factors  independently  associated  with
mortality  between  1  month  and  24  months  after  discharge,
with  calculation  of  the  hazard  ratio  (HR).  Two  groups  were
considered  (patients  aged  <  70  years  and  patients  aged  ≥  70
years)  in  view  of  the  age-related  differences  in  patient  char-
acteristics,  especially  the  proportions  of  the  two  types  of
heart  failure.  The  standardized  survival  of  these  patients
was  also  compared  with  that  of  patients  excluded  because
of  the  absence  of  medicinal  product  reimbursement,  who
were  likely  to  be  institutionalized.  SAS  version  4.3  software
was  used  (SAS  Institute  Inc,  Cary,  NC,  USA).
Results
For  the  overall  population  of  general  scheme  beneﬁciaries,
152,601  hospitalizations  for  heart  failure  were  identiﬁed  in
2009,  corresponding  to  130,333  patients;  69,958  (53%)  of
these  patients  were  hospitalized  for  heart  failure  for  the
ﬁrst  time  (48%  men;  mean  age,  78  ±  3  years).
Survival
One  and  2-year  survival  rates  were  71%  and  60%,  respec-
tively.  One  and  2-year  survival  rates  without  readmission
for  heart  failure  after  hospital  discharge  were  55%  and  43%,
respectively,  and  without  all-cause  readmission  were  lower,
at  27%  and  17%,  respectively  (Table  1).  First  readmission
rates  for  heart  failure  among  those  patients  still  alive  at
the  end  of  the  period  considered  were  5%  at  1  month  and
14%  at  6  months  and  then  stabilized  to  reach  16%  at  2  years.
Readmission  rates  for  heart  failure  were  higher  in  youngest
patients,  who  also  had  the  highest  survival  rates.
Mortality
The  2-year  mortality  rate  was  higher  than  that  in  a  ran-
dom  sample  of  about  600,000  beneﬁciaries:  40%  for  all  ages
combined  and  45.5%  for  patients  aged  ≥  75  years  (Fig.  1).
The  age-  and  sex-standardized  RR  of  death  was  29  (95%  CI
28—29)  for  all  patients  hospitalized  for  heart  failure,  31  (95%
CI  30—32)  for  women  and  27  (95%  CI  26—28)  for  men.  The  RR
was  higher  among  the  youngest  patients  and  decreased  with
age:  <  50  years,  RR  82  (95%  CI  72—94);  50—59  years,  RR  17
(95%  CI  15—19),  60—69  years,  RR  12  (95%  CI  11—13);  70—79
patients with a ﬁrst hospitalization for heart failure in 2009, com-
pared with those of a random sample of national health insurance
beneﬁciaries (EGB). HF: heart failure; EGB, Échantillon Permanent
des Bénéﬁciaires.
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ears,  RR  7  (95%  CI  7—7);  80—89  years,  RR  4  (95%  CI  4—4);  ≥
0  years,  RR  3  (95%  CI  3—3).
eadmissions
he  rate  of  at  least  one  all-cause  readmission  among  sur-
ivors  was  69%  and  remained  relatively  stable  according  to
ge  (Table  2).  A  diagnosis  of  heart  failure  was  reported  for
4%  of  ﬁrst  readmissions  and  another  cardiovascular  disease
as  reported  for  22%,  i.e.  46%  overall  for  all  cardiovascu-
ar  diseases.  The  proportion  of  ﬁrst  readmissions  for  heart
ailure  increased  with  age,  whereas  it  decreased  for  other
ardiovascular  diseases.  The  proportion  of  readmissions  for
iseases  of  the  respiratory  system,  symptoms  and  injury  also
ncreased  according  to  age.
atient characteristics and treatmentso  medicinal  products  were  reimbursed  6  months  before
ospitalization  for  4.9%  of  all  patients  included,  while
o  medicinal  products  were  reimbursed  for  12.7%  of  30-
ay  survivors  after  the  ﬁrst  hospitalization  and  for  20%  of
5
3
b
b
Table  2 Two-year  outcome  of  survivors  after  a  ﬁrst  hospitali
the  ﬁrst  readmission  for  2-year  survivors,  according  to  age.
Age  (years)  
<  55  55
Events
Total  number  4005  10  
Readmissiona with  or  without  death  (%)  68.0  
Death  without  readmissiona (%)  5.8  
Readmissiona or  death  (%)  73.8  
Principal  diagnosis  at  the  ﬁrst  readmission
Total  number  2721  7
Cardiovascular  diseases  (%)  55.2  
Heart  failure  20.9  
Angina  pectoris  1.5  
Acute  myocardial  infarction  0.7  
Chronic  ischaemic  heart  disease  3.2  
Cardiomyopathy  8.8  
Atrial  ﬁbrillation  and  atrial  ﬂutter  6.0  
Cerebral  infarction  0.4  
Other  cardiovascular  diseases  13.7  
Tumours  (%)  4.2  
Endocrine  diseases  (%)  4.4  
Diseases  of  the  nervous  system  (%)  2.6  
Diseases  of  the  eye  and  adnexa  (%) 0.4  
Diseases  of  the  respiratory  system  (%)  5.0  
Diseases  of  the  digestive  system  (%) 4.5 
Diseases  of  the  genitourinary  system  (%) 4.0
Symptoms,  signs  and  abnormal  clinical
and  laboratory  ﬁndings  (%)
5.7 
Injury  (%)  2.2  
Factors  inﬂuencing  health  status  (%)  3.7  
Other  (%)  8.1  
Total  (%)  100.0  
a At least one all-cause readmission.P.  Tuppin  et  al.
atients  aged  ≥  90  years  (Table  3).  A  total  of  53,168  patients
ere  still  alive  at  1  month  and  had  at  least  one  all-class
edicinal  product  reimbursed  within  6  months  before  hos-
italization  and  the  month  following  hospitalization.  These
atients  had  a  mean  age  of  77  ±  3  years,  51%  were  women
nd  74%  presented  at  least  one  co-morbidity.  During  the
ear  preceding  hospitalization,  42%  had  had  at  least  one
rain  natriuretic  peptide  (BNP)  assay  and  48%  had  been
xamined  by  echocardiography  or  had  consulted  a  car-
iologist.  During  the  ﬁrst  month  after  discharge,  30%  of
atients  had  consulted  a  cardiologist,  79%  had  consulted
heir  general  practitioner  and  17%  had  had  at  least  one  BNP
ssay.
Reimbursement  rates  for  standard  heart  failure  car-
iovascular  treatments  within  6  months  prior  to  before
ospitalization  were  40%  for  beta-blockers,  56%  for
CEIs/ARBs,  60%  for  diuretics  and  19%  for  aldosterone  antag-
nists.  Treatment  frequencies  30  days  after  discharge  were
4%  for  beta-blockers,  67%  for  ACEIs/ARBs,  85%  for  diuretics,
4%  for  aldosterone  antagonists  and  37%  for  the  beta-
locker,  diuretic  and  ACEI/ARB  combination.  Treatment  with
eta-blockers  and  ACEIs/ARBs  was  more  frequent  among
zation  for  heart  failure  in  2009  and  principal  diagnosis  at
All
—69  70—79  80—89  ≥  90
731  17  600  28  888  8734  69  958
72.1  73.0  69.0  60.0  69.0
8.0  10.0  15.8  28.4  14.3
80.1  83.0  84.8  88.4  83.3
733  12  841  19  918  5237  48  306
52.8  46.9  43.4  42.9  46.3
20.5  22.6  26.2  30.2  24.5
2.4  2.2  1.4  1.1  1.7
0.8  0.8  0.9  1.1  0.9
4.7  3.4  1.5  0.4  2.4
4.2  1.4  0.5  0.2  1.7
7.3  4.6  2.7  1.4  4.0
0.5  0.8  1.2  1.4  0.9
12.4  11.1  9.0  7.1  10.2
6.9  7.5  7.0  5.5  6.8
4.4  3.5  2.6  2.2  3.1
2.8  2.5  1.9  1.4  2.2
2.3  3.7  3.4  1.5  2.9
6.2  8.1  9.9  13.1  9.0
4.1  5.1  4.8  4.7  4.7
3.9  4.3  4.0  3.2  4.0
5.4  6.6  8.0  9.2  7.3
2.2  3.4  5.9  7.7  4.7
3.8  2.7  2.1  1.5  2.6
5.2  5.7  7.0  7.1  6.4
100.0  100.0  100.0  100.0  100.0
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Table  3  Characteristics  and  management  of  53,168  general  scheme  patients  before  and  after  a  ﬁrst  hospitalization  for
heart  failure  in  2009a,  by  age  and  sex.
Age  (years)  Womenb Menb Total
<  55  55—69  70—79  80—89  ≥  90
Total  number 4005  10  731 17  600 28  888 8734  33  408 36  550  69  958
No  medicinal  products
reimbursed  6  months
before  (%)
12.3 7.4  3.7  3.7  5.4  4.7  5.2  4.9
Number  surviving  thirty  days
after  discharge
3858  10  184  16  309  25  225  6841  32  365  30  052  62  417
No  medicinal  products
reimbursed  30  days  after
discharge  (%)
10.9  8.4  9.8  14.7  19.7  15.1  10.1  12.7
Number  with  ≥  one
reimbursement  6  months
before  and  30  days  after
3122  8810  14  444  21  317  5475  27  086  26  082  53  168
Mean  age  (years) 79.8 74.0  77.0
Women  (%) 36.3 33.5  44.4  58.5  74.2  50.9
No  ALD  chronic  disease  (%) 46.8  27.7  21.7  24.2  31.4  28.0  24.2  26.1
ALD  tumours  (%) 5.3 10.1  13.5  13.1  10.0  10.4  13.5  11.9
Other  ALD  chronic  disease
(%)
20.2 18.6 17.2 16.2  15.9  18.4  15.7  17.1
12  months
prehospitalization
At least  one  cardiology
consultation  or
echocardiography
48.5 53.3  54.5  46.4  31.1  43.6  53.2  48.3
At  least  one  BNP  assay  29.5  38.5  43.9  44.2  40.0  40.3  43.5  41.9
6  months
prehospitalization
ACEI/ARB  34.9  55.1  61.9  57.9  46.9  54.3  57.7  56.0
Beta-blocker  29.6  42.5  44.7  39.3  28.7  39.2  39.7  39.6
Diuretic  (at  least  one)  31.8  50.8  61.9  65.5  62.6  60.6  59.4  59.8
Loop  diuretic  25.2  37.2  45.8  50.6  51.6  44.3  47.7  45.7
Thiazide  diuretic  6.3  15.6  19.2  17.6  12.9  18.9  14.0  16.5
Potassium-sparing
diuretic
10.0  11.2  10.4  10.2  8.7  10.9  9.6  10.3
Potassium-sparing
diuretic  associated
8.3 9.8  9.2  8.9  7.5  9.5  8.3  8.9
During  the  ﬁrst  month
posthospitalization
At  least  one  cardiology
consultation  or
echocardiography
32.0 35.5  33.4  28.8  19.8  27.8  33.1  30.4
At  least  one  GP
consultation
68.7 73.9  80.2  82.0  82.8  81.3  77.5  79.5
At  least  one  BNP  assay  13.3  16.1  16.8  17.6  17.0  16.4  17.3  16.8
Beta-blockers  65.2  64.1  57.7  49.2  36.3  52.4  53.9  53.6
ARB  13.1  21.5  24.3  21.3  15.3  23.7  18.6  21.1
ACEI  61.6  55.4  48.9  42.9  36.3  43.0  50.5  47.0
ACEI  or  ARB  72.5  74.6  71.4  63.1  51.0  65.0  67.7  66.6
Diuretic  (at  least  one)  75.5  82.8  86.4  86.8  85.1  85.0  85.6  85.2
Loop  diuretic  70.4  77.4  81.5  83.0  82.9  80.2  81.8  80.9
Thiazide  diuretic  5.4  9.2  9.3  7.3  4.6  8.8  6.9  7.8
Potassium-sparing
diuretic
30.3  24.7  18.4  14.1  9.4  16.7  17.9  17.5
Potassium-sparing 27.7 23.1  17.3  13.3  9.0  15.8  16.7  16.4
diuretic  associated
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Table  3  (Continued  )
Age  (years)  Womenb Menb Total
<  55  55—69  70—79  80—89  ≥  90
Potassium 25.6 29.5 31.7  34.2  33.6  32.9  31.3  32.2
Calcium  channel  blocker  13.4  22.1  25.5  23.9  22.4  24.4  22.0  23.3
Cardiotonic  steroid  8.1  10.3  11.5  13.5  14.2  13.7  10.4  12.2
Class  III  antiarrhythmic  15.0  24.2  27.0  24.7  20.0  23.2  24.8  24.2
Oral  anticoagulant  28.0  36.6  43.2  41.0  23.0  37.8  38.5  38.3
Platelet  aggregation
inhibitor
37.1 50.9  48.9  45.3  49.8  41.5  52.5  47.2
Lipid-lowering  agent  33.1  54.2  52.9  37.8  16.3  37.1  47.0  42.1
Antidiabetics  16.8 34.9 33.2  20.8  10.2  25.5  25.2  25.2
Combinations
ACEI/ARB  only  2.9  2.9  2.5  2.6  3.0  2.7  2.7  2.7
Beta-blocker  only  3.1  2.6  2.2  1.8  1.7  2.3  2.0  2.1
Diuretic  only  8.7  8.6  11.0  16.3  25.6  14.7  13.8  14.1
ACEI/ARB  +  diuretic 13.4  18.8  23.8  25.7  26.6  23.6  23.7  23.4
ACEI/ARB  +  beta-blocker  8.8  6.1  3.9  2.6  1.6  3.5  3.9  3.8
Beta-blocker  +  diuretic 6.0  8.6  10.4  12.6  13.2  11.5  10.7  11.0
Beta-blocker  +  ACEI/ARB 47.3 46.9  41.2  32.2  19.8  35.1  37.4  36.7
ACEI: angiotensin-converting enzyme inhibitor; ALD: affections de longue durée (chronic diseases); ARB; angiotensin receptor blocker;
BNP: brain natriuretic peptide; GP: general practitioner.
a Among patients surviving at least 30 days after discharge with at least one all-class medicinal product reimbursement during these 30
days and during the 6 months preceding hospitalization.
b Adjustment for age.
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she  youngest  patients  (64%  and  75%  in  the  55—69  years  age
roup,  respectively).
actors associated with mortality between 1
nd 24 months
his  analysis  concerned  the  53,168  survivors  at  1  month  with
t  least  one  medicinal  product  reimbursement  (Table  4).
avourable  prognostic  factors  on  multivariate  analysis  for
atients  aged  <  70  years  were:  female  sex;  aged  <  55  years;
bsence  of  ALD  chronic  disease;  and,  1  month  after
ischarge,  treatment  with  ACEI/ARB,  beta-blocker,  lipid-
owering  agent,  oral  anticoagulant  or  calcium  channel
locker  and  at  least  one  cardiology  consultation  or  echocar-
iography.  Poor  prognostic  factors  included  the  presence  of
n  ALD  chronic  disease  status  for  tumour,  treatment  with
 loop  diuretic  before  and/or  after  hospitalization  and,  1
onth  after  discharge,  readmission  for  heart  failure  and  at
east  one  BNP  assay.  These  factors  were  similar  for  patients
ged  ≥  70  years,  but  with  lower  hazard  ratio  values.  Notable
upplementary  favourable  prognostic  factors  in  this  older
opulation  were  diabetes  and  at  least  one  BNP  assay  during
he  year  preceding  hospitalization;  poor  prognostic  factors
ere  at  least  one  cardiology  consultation  or  echocardiogra-
hy  during  the  year  preceding  hospitalization.
Patients  surviving  at  1  month  with  no  medicinal  product
eimbursement  were  more  likely  to  be  women  (62%  vs  50%)
nd  older  (mean  age,  79  years  vs  77  years).  After  adjust-
ent,  6-month,  1-year  and  2-year  mortality  rates  were  21%,
0%  and  43%,  respectively.  These  rates  were  signiﬁcantly
igher  than  those  in  patients  with  at  least  one  medicinal
l
m
h
rroduct  reimbursement  during  the  month  after  discharge
11%,  20%  and  33%,  respectively).
iscussion
his  large-scale  real-life  study  of  69,958  patients  hospital-
zed  for  the  ﬁrst  time  for  heart  failure  revealed  a  high
ortality  rates  in  this  population:  6.4%  in  hospital,  11%  at  1
onth,  29%  at  1  year  and  40%  at  2  years.  The  2-year  mor-
ality  rate  was  29-fold  higher  than  that  in  a  large  control
ample.
ortality
n  improvement  in  the  short-term  hospital  mortality  of
eart  failure  has  been  reported  in  the  United  States  among
eterans  (mean  age,  70  years;  2002—2006)  and  Medicare
atients  (mean  age,  80  years;  1993—2006),  with  mortality
ates  during  the  ﬁrst  hospitalization  of  about  2.8%  among
eterans  and  4.3%  among  Medicare  patients  [9,19].  These
ates  are  lower  than  the  6.4%  mortality  rate  observed  in
ur  study,  which  only  considered  the  ﬁrst  hospitalizations
f  patients  with  a  mean  of  age  of  78  years,  and  the  10.4%
ortality  rate  observed  in  Canada  in  2004  among  patients
ged  ≥  20  years  [20]. Although  the  mean  length  of  hospital
tay  is  decreasing  in  the  USA,  an  increased  rate  of  transfer  to
ong-stay  or  rehabilitation  units  has  also  been  observed.  The
ean  length  of  stay  was  6  days  for  Medicare  beneﬁciaries
ospitalized  in  2008  versus  9  days  for  a  ﬁrst  hospitalization,
egardless  of  age,  in  our  previous  study  conducted  in  the
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Table  4  Factors  associated  with  mortality  between  1  and  24  months  among  general  scheme  patients  with  a  ﬁrst  hospi-
talization  for  heart  failure  in  2009a,  according  to  age  (Cox  models).
<  70  years  (n  =  11  932) ≥ 70  years  (n  =  41  236)
HR  CIL  CIU  P  HR  CIL  CIU  P
55—69  vs  <  55  years  1.3  1.2  1.5 *** —  —  —
80—89  vs  70—79  years  1.6  1.5  1.6 ***
≥  90  vs  70—79  years  —  2.4  2.3  2.6 ***
Women  0.8  0.7  0.9 *** 0.8  0.7  0.8 ***
No  ALD  chronic  disease  0.6  0.5  0.7 *** 0.8  0.8  0.8 ***
ALD  tumours  2.0  1.8  2.3 *** 1.2  1.2  1.3 ***
Other  ALD  chronic  disease 1.3 1.1  1.4 *** 1.1  1.1  1.2 ***
12  months  prehospitalization
At  least  one  cardiology
consultation  or  echocardiography
0.9 0.8  0.9 ***
At  least  one  BNP  assay  1.1  1.0  1.1 ***
6  months  prehospitalization
Beta-blocker  0.9  0.9  1.0 ***
Loop  diuretic 1.5  1.4  1.7 *** 1.4  1.3  1.4 ***
Thiazide  diuretic 0.9  0.9  1.0 **
Potassium-sparing  diuretic 1.1  1.0  1.2 ***
First  30  days  posthospitalization
ACEI/ARB  0.7 0.6  0.7 *** 0.8  0.8  0.8 ***
Beta-blocker  0.7 0.7  0.8 *** 0.9  0.9  1.0 ***
Loop  diuretic 1.3 1.2  1.5 ***
Thiazide  diuretic 0.9  0.8  0.9 ***
Calcium  channel  blocker 0.9 0.8  1.0 * 0.9  0.8  0.9 ***
Oral  anticoagulant 0.8 0.8  0.9 *** 0.8  0.8  0.9 *
Platelet  aggregation  inhibitor 1.0  1.0  1.1 ***
Lipid-lowering  agent  0.9  0.8  0.9 ** 0.8  0.8  0.8 ***
At  least  one  readmission  for
heart  failure
1.8  1.6  2.0 *** 1.7  1.6  1.8 *
At  least  one  GP  consultation  1.0  1.0  1.1 ***
At  least  one  cardiology
consultation  or  echocardiography
0.9 0.8  1.0 ** 0.8  0.8  0.9 *
BNP  assay  1.2  1.1  1.4 **
ACEI: angiotensin-converting enzyme inhibitor; ALD: affections de longue durée (chronic diseases); ARB; angiotensin receptor blocker;
BNP: brain natriuretic peptide; CIL: conﬁdence interval lower bound; CIU: conﬁdence interval upper bound; GP: general practitioner;
HR: hazard ratio.
a Among patients surviving at least 30 days after discharge with at least one all-class medicinal product reimbursement during these 30
days and during the 6 months preceding hospitalization.
* P < 0.05.
**
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6P < 0.01.
*** P < 0.001.
same  population  [19,21].  This  reduction  in  hospital  mortality
may  therefore  have  an  impact  on  the  30-day  mortality  rate
regarding  the  reduction  in  mean  length  of  stay.  For  example,
the  30-day  mortality  rate  in  the  USA  was  8%  among  Veterans
but  11%  among  Medicare  beneﬁciaries  in  2006,  similar  to  the
rate  observed  in  the  present  study.  In  Scotland,  the  30-day
mortality  rate  after  a  ﬁrst  hospitalization  for  heart  failure
had  decreased,  but  in  2003  it  was  still  about  16%  for  patients
with  a  similar  mean  age  to  those  in  the  present  study  [7].
The  1-year  mortality  rate  after  a  ﬁrst  hospitalization  for
heart  failure  was  29%  in  our  study,  higher  than  the  24%  1-
year  mortality  rate  reported  in  Scotland,  where  the  early
mortality  rate  was  higher,  and  similar  to  the  30%  1-year
mortality  rate  reported  in  the  USA  in  2008  for  all  hospitaliza-
tions  for  heart  failure  among  Medicare  beneﬁciaries  [6,7]. In
f
t
o
rorcester,  USA,  the  1-year  and  2-year  mortality  rates  after
he  ﬁrst  hospitalization  for  heart  failure  in  2000  for  patients
ith  a  mean  age  of  76  years,  close  to  that  in  our  study,  were
8%  and  40%,  respectively,  similar  to  the  rates  observed  in
ur  study  (29%  and  40%)  [22].
Few  data  are  available  concerning  the  highest  2-year
ortality  rate  after  a  ﬁrst  hospitalization  for  heart  failure.
n  Icelandic  study  conducted  in  a  population  of  patients
ged  ≥  57  years  living  in  the  community  reported  1-year,
-year,  5-year  and  7-year  mortality  rates  of  26%,  35%,  55%,
8%,  respectively,  versus  3%,  6%,  20%  and  30%,  respectively,
or  matched  controls  without  heart  failure,  corresponding
o  an  RR  at  2  years  of  about  6,  slightly  less  than  the  RR
f  8  for  this  age  group  in  our  study  [15].  Our  study  also
eported  a much  higher  mortality  rate  for  the  youngest
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atients.  Apart  from  the  different  pathophysiological  sett-
ngs  of  heart  failure  according  to  age,  this  phenomenon  can
lso  be  attributed  to  differences  in  the  frequency  of  co-
orbidities  between  patients  and  controls.  A  previous  study
n  this  same  population  demonstrated  high  rates  of  coro-
ary  heart  disease,  cardiac  arrhythmias  and  valvular  heart
isease,  as  well  as  other  diseases,  such  as  diabetes  and
alignant  tumours  (particularly  breast  and  haematopoietic
issues),  and  higher  rates  of  antipsychotic  drug  use  among
atients  aged  55—69  years  with  heart  failure  [21]. In  this
tudy,  readmissions  for  ischaemic  heart  disease,  cardiomy-
pathy  or  arrhythmia,  which  can  be  responsible  for  systolic
eart  failure,  were  also  more  frequent  among  the  youngest
atients,  and  the  highest  HR  was  observed  for  at  least  one
eadmission  for  heart  failure  during  the  30  days  after  dis-
harge.  In  contrast,  a  poor  survival  rate  was  observed  for
nstitutionalized  patients  with  no  medicinal  product  reim-
ursements  after  standardization  for  sex  and  age.  However,
nstitutionalization  of  these  patients  could  be  justiﬁed  by  a
igher  rate  of  severe  disability,  co-morbidity  and  a  poorer
eneral  state  of  health  [23—25].
eadmissions
he  national  study  on  all  hospitalizations  for  heart  failure  in
rance  in  2008  reported  a  readmission  rate  for  heart  failure
uring  the  calendar  year  of  20%,  and  75%  of  these  read-
issions  occurred  during  the  ﬁrst  3  months  after  discharge.
n  the  present  study,  1-month  and  1-year  heart  failure  ﬁrst
eadmission  rates  were  9%  and  18%,  and  all-cause  rates  were
2%  and  63%,  respectively.  The  1-month  heart  failure  read-
ission  rate  among  Veterans  in  the  USA  increased  between
002  and  2006,  but  was  6%  in  2006  [9].  For  Medicare  patients,
he  1-month  all-cause  readmission  rate  was  similar  to  that
n  our  study  (22%)  [19].  Compared  with  our  study,  the  1-year
ll-cause  readmission  rate  was  a  little  higher  (63%  vs  66%)
or  Medicare  patients  [23].  A  study  conducted  in  the  USA  in
atients  with  a  similar  mean  age  to  those  in  our  study  and
ith  a  mean  follow-up  of  almost  5  years,  reported  that  40%
f  readmissions  were  due  to  cardiovascular  disease  versus
6%  of  ﬁrst  readmissions  in  our  study  [26].  Readmissions  for
ther  diagnoses,  such  as  injury  or  diseases  of  the  respira-
ory  system,  increased  with  age  in  our  study  and  tended  to
orsen  the  prognosis  of  the  heart  failure  and  make  man-
gement  of  heart  failure,  especially  drug  treatment,  more
ifﬁcult.
reatments and management at 30 days
n  this  study  based  on  a  population  with  a  mean  age  of  77
ears,  treatment  frequencies  30  days  after  discharge  were
4%  for  beta-blockers,  47%  for  ACEIs,  67%  for  ACEIs/ARBs,
5%  for  loop  diuretics  and  34%  for  aldosterone  antagonists.
he  French  FUTURE  study  conducted  in  2008  did  not  observe
ny  differences  in  treatment  frequencies  on  discharge  from
ospital  and  at  follow-up  visits  between  patients  with  a  left
entricular  ejection  fraction  >  40%  (44%  of  patients)  or  <  40%
56%  of  patients)  [16].  Among  these  1137  patients  (mean
ge,  72  years)  followed  by  an  ofﬁce  cardiologist,  74%  were
reated  with  beta-blockers,  83%  with  an  ACEI/ARB,  86%
ith  a  loop  diuretic  and  31%  with  an  aldosterone  antag-
nist.  The  French  IMPACT  RECO  study  in  2005,  based  on
t
o
a
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000  patients  with  New  York  Heart  Association  grade  III  and
V  systolic  heart  failure  (mean  age,  70  years)  followed  by
fﬁce  cardiologists,  revealed  very  similar  treatment  fre-
uencies:  70%  for  beta-blockers,  68%  for  ACEIs  and  30%  for
RBs  (i.e.  91%  for  ACEIs/ARBs),  85%  for  loop  diuretics  and
5%  for  aldosterone  antagonists  [17]. Treatment  frequencies
0  days  after  discharge  in  the  present  study  were  therefore
ower  than  those  reported  in  the  previous  study.  However,
atients  in  our  study  were  older  (mean  age,  77  years)
nd  probably  presented  a  higher  rate  of  contraindications
o  the  use  of  medicinal  products,  such  as  ACEIs  or  beta-
lockers,  or  non-indication  (co-morbidities,  left  ventricular
jection  fraction,  etc.).  Treatment  frequencies  were  also
igher  among  the  youngest  patients.
actors associated with mortality between 1
onth and 24 months
he  favourable  effect  on  survival  of  follow-up  by  a  cardiolo-
ist  has  already  been  reported  and  is  now  part  of  guidelines
27,28].  This  effect  can  be  explained  by  improved  manage-
ent,  but  also  by  a  better  state  of  health,  allowing  the
atient  to  attend  the  visit  with  the  cardiologist  or,  more
arely,  a  visit  by  the  cardiologist  to  the  patient’s  home  or
nstitution.  This  real-life  study,  like  similar  studies  or  clinical
rials  [12,22,24,25,29],  demonstrated  a beneﬁcial  effect  of
eta-blockers  and  ACEIs/ARBs  on  the  survival  of  young  sub-
ects.  Nevertheless,  this  effect  was  also  observed  in  older
atients,  who  are  rarely  recruited  in  clinical  trials.  How-
ver,  older  patients  treated  with  these  agents  could  be
he  subject  of  indication  biases  related  to  the  pathophy-
iology  of  heart  failure  and  their  clinical  state.  Thiazide  and
otassium-sparing  diuretics  have  a  beneﬁcial  effect  in  these
lder  patients,  but  the  use  of  loop  diuretics  has  a  nega-
ive  prognostic  impact  for  the  two  age  groups.  These  drugs
ay  be  prescribed  for  relief  of  symptoms,  in  accordance
ith  guidelines,  but  they  may  also  indicate  a  clinical  stage
ssociated  with  severe  symptoms,  reﬂecting  more  advanced
isease  [12].
tudy limitations
ertain  groups  of  the  French  population,  such  as  civil  ser-
ants,  liberal  professionals  and  farmers,  were  not  included
n  this  study  due  to  their  occupation,  as  they  are  covered
y  other  health  insurance  schemes.  This  study  was  based
n  patients  hospitalized  for  the  ﬁrst  time  for  acute  heart
ailure,  but  some  of  them  probably  already  had  a  diag-
osis  of  chronic  heart  failure:  42%  had  had  at  least  one
NP  assay  during  the  previous  year  and  19%  were  already
reated  with  an  aldosterone  antagonist.  The  possibility  of
rst  hospitalizations  before  2006  (i.e.  >  3  years  before  the
nclusion  period  of  this  study)  cannot  be  eliminated.  One-
ear  and  5-year  mortality  rates  of  20—30%  and  45—60%,
espectively,  have  been  reported  [1].  The  bias  is  therefore
imited.  The  data  used  in  this  study  were  derived  from  medi-
al  and  administrative  databases  that  collect  only  limited
linical  information,  such  as  those  necessary  for  the  distinc-
ion  between  systolic  and  diastolic  heart  failure,  which  is
ne  of  the  major  limitations  of  this  study.  These  databases
lso  have  the  classical  limitations  concerning  the  validity  of
ata  collection  and  data  coding  in  an  ‘‘administrative  way’’,
ilure
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[Outcome  of  patients  after  a  ﬁrst  hospitalization  for  heart  fa
such  as  coding  of  diagnoses  and  chronic  disease.  Neverthe-
less,  the  exhaustiveness  of  this  database  can  be  considered
to  be  good,  as  this  information  is  required  for  reimburse-
ment.  Estimation  of  chronic  disease  status  using  ALD  could
be  underestimated  because  the  100%  reimbursement  of
healthcare  expenditure  is  not  useful  for  institutionalized
people,  those  with  mutual  insurance  or  those  with  a  pre-
existing  ALD.  Some  frequencies  could  be  underestimated,
especially  for  laboratory  assays  performed  in  public  hospi-
tals  or  reimbursement  of  certain  medicinal  products  when
they  are  dispensed  during  a  stay  in  an  institution.
Conclusions
Short-term  and  medium-term  readmission  and  mortality
rates  after  a  ﬁrst  hospitalization  for  heart  failure  are
extremely  high.  Despite  the  limitations  of  the  databases
used  for  this  study,  there  still  appears  to  be  room  for
improvement  in  the  drug  treatment  prescribed  on  discharge,
in  terms  of  frequency  and  combination  therapies,  in  order
to  lower  the  readmission  rate.  Physicians  managing  these
patients  must  prescribe  recommended  medicinal  products
at  effective  doses,  while  stressing  the  importance  of  adher-
ence,  and  they  must  therefore  provide  attentive  patient
education  concerning  the  presence  of  possible  risk  factors
for  decompensation.  As  mentioned  in  the  introduction,  dis-
ease  management  programmes  have  been  demonstrated  to
be  effective  in  many  trials,  in  terms  of  readmission  rates  and
quality  of  life,  and  are  therefore  now  included  in  clinical
practice  guidelines.  The  French  national  health  insurance
fund  (CNAMTS)  is  currently  developing  a  return-home  and
follow-up  management  programme  (PRADO)  for  patients
hospitalized  for  heart  failure,  in  partnership  with  general
practitioners.
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